Consciousness may emerge not from code, but from the way living brains physically compute.

And, as we changed this means of interaction rather quickly, one way we did it has to do with games. Game engines are now AI ...

Knowable Magazine reports 2025 faced turmoil in U.S. science amid job cuts and budget slashes, yet saw advances in gene ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here’s what investors need to know. What To Know: The stock spiked on ...

Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a ...

WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin ...

Vaccines that resemble viruses generally produce a stronger immune response, while mRNA versions are much quicker and cheaper to make. Now we are getting the best of both worlds, in the form of mRNA ...